Herbimycin A, a benzoquinoid ansamycin antibiotic, was demonstrated t o decrease intracellular phosphorylation by protein tyrosine kinase (PTK). In Philadelphia chromosome (Phl)-positive leukemias such as chronic myelogenous leukemia (CML) and Phl-positive acute lymphoblastic leukemia (ALL), both of which express bcr-ab1 fused gene products (P2106cr-a*/ or P1906cr-ab/ protein kinase) with augumented tyrosine kinase activities, herbimycin A markedly inhibited the in vitro growth of the Phl-positive ALL cells and the leukemic cells derived from CML blast crisis. However, the same dose of herbimycin A did not inhibit in vitro growth of a broad spectrum of Phl-negative human leukemia cells, and several other protein kinase antagonists also displayed no preferential inhibition. Furthermore, we demonstrated that herbimycin A has an antagonizing effect on the growth of transformed cells by a transfection of retroviral amphotrophic vector expressing P2106crla*/ into a murine interleukin (IL)-3-HILADELPHIA CHROMOSOME (Phl) results from P a reciprocal translocation between the long arms of chromosome 9 and 22, t(9;22)(q34;qll).l It is found in more than 90% of cases of chronic myelogenous leukemia (CML), 5% of childhood acute lymphoblastic leukemia (ALL) cases, and more than 20% of adult ALL cases. The breakpoints on chromosome 22 are clustered within a 5.8-kb region referred to as the major breakpoint cluster region (M-bcr) in CML and in approximately half of Phl-positive ALL cases. The breakpoints in the other half of Phi-positive ALL are present within the first intron of bcr genes.*s3 The c-ab1 gene translocated from chromosome 9 to 22 fuses to 5' bcr sequences in juxtaposition. From the resulting fused bcr-ab1 genes, hybrid bcr-ab1 proteins of 210 Kd or 190 Kd are produced in CML and Phl-positive ALL presenting M-bcr rearrangement or in Phl-positive ALL containing the breakpoints of the first intron of bcr genes, re~pectively!-~ These proteins exhibit augmented protein dependent myeloid FDC-P2 cell line. This inhibition was abrogated by the addition of sulfhydryl compounds, similar to the reaction previously described for Rous sarcoma virus transformation. The inhibitory effect of herbimycin A on the growth of Phl-positive cells was associated with decreased bcrf ab1 tyrosine kinase activity, but no decrease of bcr-ab1 mRNA and protein, suggesting that the inactivation of bcrab1 tyrosine kinase activity by herbimycin A may be induced by its binding t o the bcr-ab1 protein portion that is rich with sulfhydryl groups. The present study indicates that herbimycin A is a beneficial agent for the investigation of the role of the bcr-ab1 gene in Phl-positive leukemias and further suggests that the development of agents inhibiting the bcr-ab1 gene product may offer a new therapeutic potential for Phl-positive leukemias.
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tyrosine kinase (PTK) activity as compared with the normal P145 product of the c-ab1 gene.s Herbimycin A, isolated from the cultured filtrate of Streptomyces sp MH237-CF-8, causes reversion of the transformed Rous sarcoma virus-infected rat kidney cell to normal morphology and reduces P6o"c protein kinase activity in these cells.9 Furthermore, herbimycin A is also effective against various cells transformed by other oncogenes that code tyrosine kinase, including v-ab1 gene, although it is not effective against ras, raf or myc-associated transformation.1° We examined the effect of herbimycin A on the growth of Phl-positive leukemia cells and the bcrlabl tyrosine kinase. We report the antagonizing effect of herbimycin A on the P21W'ab' oncoprotein-associated transformation and report that herbimycin A is more efficient at inhibiting the in vitro growth of Phl-positive leukemia cells via the suppressed bcrlabl PTK activity than it is at inhibiting that of Phl-negative leukemia cells.
MATERIALS AND METHODS

Chemicals.
Herbimycin A was isolated as described previously9 and was used at a concentration of less than 1.0 pg/mL throughout the study. Dithiothreitol (DTT) and 2-mercaptoethanol (2-ME) were purchased from Nacalai Tesque (Kyoto, Japan) and Wako Pure Chemical (Osaka, Japan). Genistain and staurosporine were purchased from Sigma (Munich, Germany). 1-(5-Isoquinolinesulfonyl)-2-methylpiperazine dihydrochrolide (H-7) and N-(6-aminohexyl)-5-chloro-l-naphthalenesulfonamide hydrochloride (W-7) were purchased from Seikagaku Kogyo (Tokyo, Japan).
Transfection of retroviral vector expressing P210bcr/ab' into interleukin-3-dependent FDC-P2 cells. Five million FDC-P2 cells" were added to a mixture of 30 )IL Lipofectin (GIBCO, Berlin, Germany) and 4 pg of pGD210 retroviral vectors expressing P210bc"ub' oncoprotein12 (Fig 1) . The cells were cultured for 16 hours in serum-free Opti-MEM I (GIBCO) in the presence of recombinant murine interleukin IL-3 (rmIL-3) prepared from COS-1 cells transfected with pSV2,,, containing mIL-3 cDNA (kindly provided by M. Kobayashi, Hokkaido University School of Medicine). The cells were selected in RPMI 1640 medium to which 10% fetal bovine serum (FBS) and 600 pg/mL Geneticin ((3418 sulfate; GIBCO) were added in the presence of rmIL-3 for 10 days. Geneticin-resistant cells were washed and plated in medium lacking rmIL-3 to select for IL-3-independent growth.
Three Phl-positive ALL cell lines, the TOM-1 cells, the ALL/MIK cells, and the MR-87 cells, and the MC3 cells derived from CML of myeloid crisis have been described previ~usly.'~-'~ MR-87 cells were kindly provided by Dr J. Okamura (Kyushu National Cancer Institute, Kyushu, Japan). -glutamine, 100 U/mL penicillin G, and 100 pg/mL streptomycin in the presence of 10 ng/mL recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and 100 U/mL rhIL-3 for 7 days, and were then assayed. The thawed cells that showed greater than 85% viability (>80% leukemic cells) were then assayed. The fresh leukemic cells of Phl-positive ALL case IY, CML blast crisis cases SM and YT, and other leukemia cases presenting no Phl were obtained from heparinized peripheral blood by Ficoll-Conray gradient density sedimentation.
The assay of cellular proliferation was performed using 3H-thymidine (3H-TDR) incorporation and/or Colorimeric (MTT) methods. As for the incorporation of 3H-TdR, the cells (1 x to4) were suspended in RPMI 1640 containing 10% FBS and cultured with or without herbimycin A for 96 hours in a humidified atmosphere with 5% C02 at 37°C. The cultures were pulsed with 3H-TdR (0.5 pCi/well) for the last 4 hours before termination and then harvested by an automatic cell harvester. Radioactivity was measured in a liquid scintillation counter and expressed as mean cpm 2 SD in triplicate cultures. MTT proliferation assay was performed using a modified method described by Mosmann.zo In brief, the cells were seeded in triplicate in 100 pL of media in 96-microwell plates, and incubated in the same condition as for the 3H-TdR assay for several days. After 10 p L of a 5-mg/mL stock solution of MTT [3-(4, 5-dimethylthiazol-2, 5-diphenyl tetrazolium bromide)] (Sigma) was added to each well for the last 4 hours, formazan crystals were solibilized in 100 p L of isopropanol-0.04N HCl and the optical density at 630 nm was measured in dual-beam microplate reader.
Leukemic cell lines and patients.
In vitro growth testing for herbimycin A.
CeN cycle analysis by flow cytometry. IL-3 stimulated FDC-P2 cells or autonomously growing transformant FDC-P2 cells were analyzed for nuclear DNA content using the method previously described by Laneuville et a1. 21 Briefly, 1 X lo6 cells were suspended in a solution containing 0.1% sodium citrate, 50 pg/mL propidium iodine (PI), 50 pg/mL RNAase, and 0.1% Triton X-100. The cell cycle was estimated by the analysis of DNA content using Epics C flow cytometer (Coulter Electrics, Hialeah, FL).
The cells were cultured with or without herbimycin A for 16 hours, harvested, and washed with phosphate-buffered saline (PBS). PTK activity was assayed according to the modified method of Swarup et a1,22 previously described in detail.15 Briefly 1 x lo7 cells were suspended in 0.25 mol/L sucrose-Tris buffer (pH 7.5) added to 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), 50 mmol/L 2-mercaptoethanol, and 1.5 mmol/L EGTA, followed by homogenization with a Dounce homogenizer. The homogenates were centrifuged at 1,OOOg for 10 minutes to remove the nuclear fraction and unbroken cells. The resultant supernatant fluid was then centrifuged at 105,OOOg for 60 minutes to prepare the soluble (cytosole) fraction and the particulate fraction. The particulate fraction was suspended in sucroseTris buffer by sonication. The 200-pL reaction volume contained 50 mmol/L Tris-CI (pH 7.9, 50 mmol/L MgC12, 10 pmol/L vanadate, 10 pmol/L ZnCl2, and sample (30 pg of protein derived from cells); synthetic random polymer (molecular weight, 46,000, ratio of glutamine to tyrosine, 4:l; Sigma) was used as the substrate. The assay was initiated by the addition of 50 pmol/L (y-32P)adenosine triphosphate (ATP). After a 10-minute incubation at 30°C, the reaction was halted by the addition of 5% trichloroacetic acid, and bovine serum albumin was then added. The precipitated protein was removed by centrifugation and the supernatant fluid was stopped on phosphocellulose paper. The dried papers were counted for radioactivity in a scintillation counter. Appropriate reaction mixtures containing no synthetic random polymer served as control samples.
Western blotting and immune complex kinase assay of bcr/abl. For Western blotting, 1 x lo7 cells were disrupted in 50 mmol/L sodium phosphate (pH 7.5), 1% Triton X-100, 1 mmol/L PMSF fluoride with sonication. The lysate was centrifuged at 10,OOOg for 20 minutes. Thirty microliters of the supernatant was then applied to 7.5% gel of sodium dodecyl sulfate (SDS)-polyacrylamide as described by LaemmLZ3 After electrophoresis, the gel was electroblotted onto Clear Blot Membrane-P (Atto, Tokyo, Japan). The membrane was prepared for blotting by washing in 2% skim milk for 1 hour at 3TC, and was then reacted with a 1:20 dilution of mouse anti c-abl monoclonal antibody, Ab-3 (Oncogene Science, Mineola, NY) overnight at 4°C. The membrane was washed with PBS with 0.05% Tween 20 four times, and was then reacted with peroxidase-conjugated rabbit anti-mouse IgG for 2 hours at room temperature. The band of antibody bound to bcrlabl protein was detected by a KONICA HR Immunostain Kit (Konica, Tokyo, Japan).
The immune complex kinase assay was performed using a modified method described by Kurzrock et al.24 Briefly, the cells (1 X lo7) were collected and washed with PBS and then lysed at
Assay of cellular PTK activity.
For personal use only. on January 1, 2018. by guest www.bloodjournal.org From 4°C by sonication in 50 mmol/L Tris-HC1 (pH 7.5), 0.15 mmol/L NaCl, 0.1% SDS, 1% Triton X-100, 0.5% sodium deoxycholate, 1 mmol/L PMSF buffer. The diluted sample was treated with mouse monoclonal antibody against c-abl, Ab-3, for 1 hour at room temperature and was incubated overnight at 4°C. Immune complex with anti-c-abl antibody was precipitated with mouse anti-IgG antibody-coated protein A (Zymed Laboratories, San Francisco, CA), and immunoprecipitates were then reacted with 5 pCi ( Y -~~P ) A T P for 10 minutes on ice. Next, immune complexes were analyzed on 7.5% SDS-polyacrylamide gels, followed by autoradiography with an intensifying screen.
RNA was extracted by the guanidinum, thiocyanate-cesium chloride method.13 In Northern blot analysis, 20 kg of total RNA was electrophoresed through 1.0% agarose containing 7% formaldehyde. After the gel was blotted onto a Biodyne membrane (Pall, Glen Cove, NY), the membrane was hybridized with a nick-translated abl-specific probe (1.5-kb BgZII fragment of pAb3).
Unless otherwise indicated, mean values 2 1 SD for measurements from triplicate culture are presented. Significance of difference was assessed using Student's t-test; results were assessed significantly different at P < .01.
Analyses of expression of bcr-ab1 mRNA.
Expression of results.
RESULTS
Herbimycin A abrogates the in vitro growth of P2lObCrlab1 expressing FDC-P2 cells. IL34ependent FDC-P2 cells were transfected with pGD210 murine retroviral vector expressing P210bcr/a61 or mock pZIPNeoSV(X) in the presence of 100 U/mL of rmIL-3 and subsequently selected with G418, followed by transfer to medium free of mIL-3. In the absence of mIL-3, parental or mock-transfected cells died within 72 hours. In contrast, G418-resistant pGD210bC'lab1 transfected cells grew in the media free of mIL-3 (Fig 2A) . A Northern blot of total RNA derived from pGD210bC'/06'-transfected transformed cells showed transcripts of bcrlabl and ne0 genes (Fig 2B) . The expression of bcrlabl was confirmed by the immune complex kinase assay of bcrlabl protein from these cells (Fig 2B) .
We have previously demonstrated that herbimycin A causes reversion of the transformed Rous sarcoma virusinfected rat kidney cells with reduction of P60"' protein kinase a~tivity.~ We investigated whether herbimycin A antagonizes pbcrlabl oncoprotein-associated autonomous growth of FDC-P2 cells transformed by the transfection of the bcrlabl gene. Herbimycin A showed no significant inhibition of the growth of parental FDC-P2 cells in the presence of mIL-3, but did show a profound inhibition of the growth of transformant FDC-P2 cells in a dosedependent fashion (Fig 3) . By cell cycle analysis, the transformant FDC-P2 cells showed an increased DNA content and a striking increase of the fraction of cells in S phase. The treatment of transformant cells with herbimycin A for 16 hours decreased the fraction of cells in G1 and S phases (Fig 4) . Furthermore, herbimycin A suppressed 3H-TdR incorporation of the leukemic cells obtained from all four Phlpositive ALL cases and two myeloid crisis cases, whereas suppression of 3H-TdR incorporation was observed in only some of the leukemic cells presenting no Phl (Fig 6) .
To clarify whether the growth inhibition of Phl-positive leukemic cells by herbimycin A is associated with the inhibition of bcr-ab1 tyrosine kinase, we performed an assay of cellular PTK activity. The cells were cultured with or without herbimycin A for 16 hours and then assayed for cellular PTK activity in the cytosole and particulate fractions. The PTK activities of both fractions were remarkably decreased in Phl-positive leukemia cell lines when compared with those of an AML cell line, AMLSq, presenting no Phl (Fig  7) . The immune complex kinase assay of bcrlabl on the K562 cells showed that herbimycin A dramatically suppressed the autophosphorylation activity of P21@r'u6[ tyrosine kinase, although it did not affect bcr-ab1 mRNA and bcrlabl protein expression (Fig 8) .
Abrogation of herbimycin A action on Phl-positive cells by the addition with sulfhydryl compounds. We have previously reported the possibility that sulfhydryl groups of p60v-s'c are involved in the inactivation of v-src tyrosine kinase activity by herbimycin A because of abrogation of the ability of herbimycin A to inactivate p60v-sK kinase, as well as the ability to reverse transformed cell morphology by the addition of a sulfhydryl compound. 25 We investigated the effect of sulfhydryl compounds such as D'IT or 2-ME on the herbimycin-induced growth inhibition of Phl-positive leukemia cells. As shown in Fig 9, 
DISCUSSION
Recent progression of study on the role of hcrlahl genes in the leukemogenesis of Phl-leukemias offers opportunities for improvements in the diagnosis and analysis of pathophysiology. In addition, the oncogenic role of hcrlahl fused protein is supportcd by the oncogenic outcome of transgenic mice or bone marrow-transplanted mice using transduction of the hcrlahl gene.12.15 Therefore, several strategies of a specific therapy for Phi-positive leukemia such as exploiting antagonists against the expression or product of hcrlahl gcnc arc warranted. For example, disturbance ofhcrlahl function with antisense oligodcoxynucleotides might offer thc possibility for a new category of leukemia thcrapy in the future.'" A recent and promising strategy for therapy may be selective inhibition of tyrosine kinase.'' Tryphostin, a derivative molecule of erbstain, which is a prototype tyrosine analogue, has been reported to block phosphorylation of tyrosine residue and inhibit epidermal growth factor (EGF)-dependent cell proliferation in vitro at concentrations showing little toxicity,% thus providing an insight into development of therapy against various types of cancers associated with amplifications of erb B-1 and -2 oncogenes. In the present study, we analyzed the effect against bcrlabl oncoprotein-associated cell proliferation of herbimycin A, a protein kinase inhibitor that we isolated on the basis of its ability to cause rat kidney cells transformed by v-src to revert from the rounded, transformed morphology to the normal, more flattened morphology with a loss of PTK activity of the transforming protein of Until now, it was believed that the antitumor effect of herbimycin A was relatively selective for cells transformed by oncogenes coding PTK such as src, yes, jjx, ros, abl, and erb B.l0 In this study, we demonstrated that herbimycin A antagonizes the transformation of IL-3-dependent murine hematopoietic cells by transfection of bcrlabl genes. Further, we showed that it effectively inhibits the in vitro growth of Phl-positive leukemia cells in less than 0.2 pg/mL concentrations exhibiting little toxicity, whereas Genistain (another inhibitor of tyrosine kinase), as well as other antagonists of protein kinase including staurosporine, H7, and W7, showed no preferential inhibition on Phl-positive leukemic cells. As these results suggest the likelihood that herbimycin A-induced inhibition of Phlpositive leukemia cells results from the inhibition on bcr-ab1 kinase, we investigated the effect of herbimycin A on the cellular PTK activity. The present study showed that herbimycin A treatment reduced the activity of cellular PTK associated with inhibition of bcrlabl kinase activity in Phl-positive leukemia cells. The inhibitory activity by herbimycin A on the in vitro growth of Phl-positive cells was abrogated by sulfhydryl compounds such as 2-ME or DTT. Similarly, we previously reported that the reversal action on Rous sarcoma virus transformation by herbimycin A was abrogated by the addition of various sulfhydryl compounds due to the formation of an adduct with a thiol compound, possibly through conjugation between the highly polarized double bonds (position 17 or 19) of the benzoquinone moiety of herbimycin A and the highly reactive sulfhydryl group of thiolsz9 (Fig 10) . On the other hand, herbimycin A exhibited no obvious inhibition on the expression of bcr-ab1 mRNA and the amount of bcrlabl oncoprotein. In addition, we have previously shown the specific inhibition of cytoplasmic PTK of P210b"'abl by herbimycin A in vitro. 30 These results suggest that the antibiotic is likely to bind reactive groups of ~6 0~"~ or bcr-ab1 protein kinase (p210 or p190) through the same mechanism as described above because of a high homology in src homology regions, including kinase domain, between both gene products. Determining the binding site of herbimycin A may offer new insights into the structural and regulatory mechanisms of the bcr-ab1 tyrosine kinase in expressing kinase activity. Herbimycin A (pg/rnl) For personal use only. on January 1, 2018. by guest www.bloodjournal.org From herbimycin A bone marrow-purging agent in autologous bone marrow transplantation of Phl-positive leukemias, and, in the future, might offer promising therapeutic potential. Investigations of these potential uses for herbimycin A, including its in vivo antitumor effect in a mouse model, are in progress. Furthermore, this study suggests the possibility that antagonists against oncogene products such as herbimycin A may provide important insights into the study of leukemogenesis 
